Anidulafungin

BreastfeedingPediatric
  • TRADE NAMES: Ecalta (Pfizer); Eraxis (Pfizer)
  • INDICATIONS: Candidemia, candidal esophagitis
  • CLASS: Antimycobacterial, echinocandin
  • HALF-LIFE: 40–50 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: C

Our database has 74 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
GENITOURINARY
HEMATOLOGIC
LOCAL
NEUROMUSCULAR/SKELETAL
OCULAR
RENAL
RESPIRATORY
OTHER


Page last updated 11/13/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top